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Background
The use of multiplex ligation-dependent probe amplifica-
tion (MLPA) to detect large scale rearrangements is now
a standard component of BRCA1 and BRCA2 gene test-
ing in the clinical setting. With the cost of full Sanger
sequencing up to 4 times higher than the cost of MLPA,
it is important not only to determine the prevalence of
these mutations but to ascertain the probability that a
family may harbour a large deletion or rearrangement in
the BRCA1 and BRCA2 genes. Here we examine the inci-
dence and clinical associations of genomic rearrange-
ments in the BRCA1 and BRCA2 genes in a cohort of
index cases from high risk breast and ovarian cancer
families recruited from familial cancer centres (FCC).
Method and results
The Victorian FCC Translational breast cancer cohort
includes 1222 index cases identified from families who
had been seen through one of the four FCCs in Victoria.
Until 2007, standard BRCA tests did not include MLPA
but instead used a variety of sequencing-based methods
which included PTT, DHPLC and Sanger sequencing.
Of these cases, 246 (20.1%) were found to carry a
BRCA1 or BRCA2 mutation using sequencing-based
methods. In a small proportion of cases MLPA was per-
formed prior to study commencement based on clinical
indications leading to the detection of 11 mutations. A
total of 965 cases were found not to carry a BRCA1 or
BRCA2 mutation through sequencing-based methods
and were eligible for MLPA in the study. A hundred
and nine cases were excluded from testing: 19 did not
fit inclusion criteria, 93 had unsuitable DNA for testing.
In the remaining 856 cases a further 24 (2.8% of cases)
BRCA1 and BRCA2 mutations were identified using
MLPA. In the total cohort of 1113 index cases, 246
(22.1%) BRCA1 and BRCA2 mutations have been identi-
fied, including 36 (14.2% of mutations) large deletions
and duplications detected through MLPA. Mean age of
onset for first breast cancer diagnosis was 41 years (26-
73) in mutation carriers detected using sequencing
based methods and 40 years (18-60) in cases with geno-
mic rearrangements detected by MLPA.
Analysis of the BRCAPRO scores revealed that the
mean BRCA carrier probabilities for BRCA mutation
carriers detected though MLPA were significantly higher
than those detected using sequencing based methods
(0.58 versus 0.37 respectively, p=0.002). Further analysis
of correlations between mutation type and patient
demographics including the cancer profile of the index
case and their 1
st -3
rd degree family members, rates of
bilateral breast cancer, male breast cancer and early age
of onset will be presented.
Conclusion
MLPA detected genomic rearrangements accounted for
14% of all BRCA mutations in a large cohort of Victorian 1Peter MacCallum Cancer Centre: Familial Cancer Centre, Australia
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any medium, provided the original work is properly cited.FCC families. The association with higher pre-test carrier
probabilities indicates that an optimal strategy for BRCA
mutation detection in which an initial MLPA screen in
high risk families may avoid the need for sequencing in
some patients where a genomic rearrangement is present,
with an associated cost saving.
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